Q1 2025 Concord Biotech Ltd Earnings Call Transcript
Key Points
- Operational revenue experienced a year-on-year growth of 11% for Q1 FY25.
- Profit before tax for the quarter grew by 20% year-on-year, excluding the share of profits from JV and associates.
- EBITDA margins for Q1 FY25 stood at 38%, a growth of 63 bps year-on-year.
- Formulation segment revenues grew by 43% in Q1 FY25 on a year-on-year basis.
- Development of the upcoming injectable facility is progressing well, expected to commercialize by the last quarter of this financial year.
- API revenue growth was relatively low at 5% year-on-year for Q1 FY25.
- Lower share of profits from JV partially impacted the PAT growth.
- There has been a delay in the commencement of the injectable facility, now expected by the beginning of Q4 FY25.
- Export revenue from international business moderated by 3% in Q1 FY25.
- Utilization rates for some facilities remain relatively low, with the Limbasi facility at 38% and formulation plant at 24%.
Ladies and gentlemen, good day, and welcome to Concord Biotech Limited Q1 FY25 earnings conference call.
This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinion, and expectation of the company as on date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict.
(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Sagar Shroff from Strategic Growth Advisors. Thank you, and over to you, sir.
Thank you, Deepika. Good afternoon, everyone, and thank you for joining us on the Q1 and FY25 earnings conference call for Concord Biotech Limited. Today, we are joined by Mr. Sudhir Vaid, Chairman and Managing Director; Mr. Ankur Vaid, Joint Managing Director and CEO; Mr. Lalit Sethi, Chief Financial Officer; and Mr. Prakash Sajnani, Compliance Officer and AVP Accounts.
We have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
